Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Relief Therapeutics Holding AG (RLFTF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0650+0.0030 (+4.84%)
At close: 3:58PM EST
Advertisement

Relief Therapeutics Holding AG

BAtiment F2/F3
Avenue de Sécheron 15
Geneva 1202
Switzerland
41 44 723 59 59
http://www.relieftherapeutics.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees10

Key Executives

NameTitlePayExercisedYear Born
Mr. Jack WeinsteinCFO & TreasurerN/AN/A1956
Dr. Gilles Della CorteChief Medical Officer107.1kN/A1955
Mr. Christiaan L. J. J. StijnenChief Commercial OfficerN/AN/A1963
Dr. Taneli Jouhikainen M.B.A., M.D.Chief Operating OfficerN/AN/AN/A
Mr. Jeremy MeinenVP of Fin. & Admin.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need. The company focuses on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications is being investigated in two U.S. Phase 2b/3 clinical trials in acute respiratory deficiency due to COVID-19, as well as in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also involved in clinical development of RLF-100 for other indications in acute and chronic lung diseases. Relief Therapeutics Holding AG is based in Geneva, Switzerland.

Corporate Governance

Relief Therapeutics Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement